

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

June 10, 2021

David Campbell, Ph.D. Chief Executive Officer Janux Therapeutics, Inc. 11099 N. Torrey Pines Road, Suite 290 La Jolla, CA 92037

Re: Janux Therapeutics, Inc.

Registration Statement on Form S-1, as amended

Exhibit Nos. 10.8, 10.9 and 10.10

Filed May 19, 2021 File No. 333-256297

Dear Dr. Campbell:

We have concluded our assessment of your redacted exhibits for compliance with applicable form requirements and will process your supplemental response and related materials in accordance with your request.

Sincerely,

Division of Corporation Finance